- Trials with a EudraCT protocol (323)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
323 result(s) found for: Genetic association.
Displaying page 7 of 17.
EudraCT Number: 2020-003312-27 | Sponsor Protocol Number: D9480C00018 | Start Date*: 2021-03-02 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of Hyperkalaemia in Patients with Symptomatic Heart Failur... | |||||||||||||
Medical condition: Hyperkalemia in Patients with Symptomatic Heart Failure. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003107-29 | Sponsor Protocol Number: N°005 | Start Date*: 2015-08-07 | |||||||||||
Sponsor Name:GALMED Pharmaceuticals LTD. | |||||||||||||
Full Title: A Phase IIb, double blind, randomized controlled clinical trial to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic- Steatohepatitis (NASH). | |||||||||||||
Medical condition: Non-alcoholic Steatohepatitis in patients with two additional features of metabolic syndrome -overweight or obesity and Diabetes Mellitus type II or pre-diabetes. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) RO (Ongoing) LT (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001092-14 | Sponsor Protocol Number: TIGEM5_USH | Start Date*: 2023-10-12 | ||||||||||||||||
Sponsor Name:FONDAZIONE TELETHON | ||||||||||||||||||
Full Title: A phase I/II open label, dose escalation study of sub-retinal administration of a “mixture of two adeno-associated viral vectors of serotype 8 containing the 5 ´- half sequence of the human MYO7A ... | ||||||||||||||||||
Medical condition: Usher syndrome (USH) is characterized by the association of sensorineural hearing loss, Retinitis Pigmentosa (RP), and, in some cases, vestibular dysfunction. It is the most frequent cause of deaf-... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013713-99 | Sponsor Protocol Number: 2009.559 | Start Date*: 2010-04-14 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: Does Cyclosporine ImpRove Clinical oUtcome in ST elevation myocardial infarction patients (CIRCUS study) | |||||||||||||
Medical condition: acute myocardial infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002846-33 | Sponsor Protocol Number: KL13332020-104A | Start Date*: 2022-10-13 | |||||||||||
Sponsor Name:Abliva AB | |||||||||||||
Full Title: An interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose, adaptive study of the efficacy of KL1333 in adult patients with primary mitochondrial disease | |||||||||||||
Medical condition: Adult patients with primary mitochondrial disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013435-38 | Sponsor Protocol Number: M10-963 | Start Date*: 2010-02-24 | ||||||||||||||||
Sponsor Name:Abbott GmbH & Co. KG | ||||||||||||||||||
Full Title: An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC) | ||||||||||||||||||
Medical condition: Advanced Hepatocellular Carcinoma (HCC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Prematurely Ended) FR (Completed) NL (Prematurely Ended) ES (Prematurely Ended) DE (Completed) CZ (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-000701-21 | Sponsor Protocol Number: CRAD001C2222 | Start Date*: 2004-11-25 |
Sponsor Name:Novartis Services AG | ||
Full Title: A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole (Femara®) as preoperative therapy of primary breast cancer in postmenop... | ||
Medical condition: Systemic treatment for breast cancer given when the primary tumors are still present in situ within the breast can result in large tumors being down-staged, which can allow for more conservative su... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004478-29 | Sponsor Protocol Number: ASL606LIOM02 | Start Date*: 2006-12-17 | |||||||||||
Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST | |||||||||||||
Full Title: DOCETAXEL AND PREDNISON IN ASSOCIATION WITH METRONOMIC THERAPY WITH CICLOPHOSPHAMIDE AND CELECOXIN IN HORMONE-REFRACTORY PROSTATIC CANCER PATIENTS : PHASE II CLINICAL TRIAL WITH PHARMACODYNAMIC AND... | |||||||||||||
Medical condition: PATIENTS WITH PROSTATIC HORMONE-REFRACTORY CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003291-38 | Sponsor Protocol Number: CA184-243 | Start Date*: 2013-03-12 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Randomized, Open-Label, Multicenter Phase II Study of Ipilimumab Retreatment versus Chemotherapy for Subjects with Advanced Melanoma who Progressed after Initially Achieving Disease Control with ... | |||||||||||||
Medical condition: Advanced Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) BE (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001859-39 | Sponsor Protocol Number: TEDY | Start Date*: 2013-10-02 | ||||||||||||||||
Sponsor Name:Leiden University Medical Center | ||||||||||||||||||
Full Title: TElmisartan in the management of abDominal aortic aneurYsm (TEDY) | ||||||||||||||||||
Medical condition: Abdominal aortc aneurysm | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006114-14 | Sponsor Protocol Number: 62326B1658 | Start Date*: 2012-04-17 |
Sponsor Name:Research and Development department | ||
Full Title: “Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on tr... | ||
Medical condition: Hypogonadism Type 2 Diabetes Cardiovascular risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002480-15 | Sponsor Protocol Number: M14REP | Start Date*: 2014-10-15 | ||||||||||||||||
Sponsor Name:The Dutch Working Group on Immunotherapy of Oncology (WIN-O) | ||||||||||||||||||
Full Title: A Phase II, Open-Label, Multicenter Study of Vemurafenib plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Metastatic Melanoma; Response Monitoring and Resistance Prediction with Positron E... | ||||||||||||||||||
Medical condition: BRAFV600-mutation positive patients with unresectable stage IIIc or IV melanoma. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013267-19 | Sponsor Protocol Number: ILR4660g | Start Date*: 2009-10-16 | |||||||||||
Sponsor Name:GENENTECH, Inc. | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY TO EVALUATE LEBRIKIZUMAB (MILR1444A) IN ADULT PATIENTS WITH ASTHMA WHO ARE NOT TAKING INHALED CORTICOSTEROIDS (MOLLY) | |||||||||||||
Medical condition: Asthma in adult patients not taking inhaled corticosteroids | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003529-36 | Sponsor Protocol Number: mRNA-3927-P101 | Start Date*: 2020-12-18 | |||||||||||
Sponsor Name:ModernaTX, Inc | |||||||||||||
Full Title: A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants with Propionic Acidemia | |||||||||||||
Medical condition: Propionic Acidemia- Propionic acidemia is an autosomal recessive disorder caused by loss-of-function mutations in PCCA or PCCB (and in rare instances, mutations in both PCCA and PCCB), resulting in... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002532-24 | Sponsor Protocol Number: HER2 PG study | Start Date*: 2007-05-10 | |||||||||||
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Pharmacogenetic study of FcγRIIIa and HER2 genes in relation to treatment of breast cancer | |||||||||||||
Medical condition: Breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004487-53 | Sponsor Protocol Number: 2312/2007 | Start Date*: 2007-12-13 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA PISANA | |||||||||||||
Full Title: Pilot study of association of VEGF polymorphisms with clinical efficacy and tolerability of therapy in patients affected by exudative (neovascular) age-related macular degeneration. | |||||||||||||
Medical condition: Exudative and atrophic age-related macular degeneration. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001585-29 | Sponsor Protocol Number: VX15-809-111 | Start Date*: 2016-12-21 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of Lumacaftor/Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis Who Have an A455E-CFTR... | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002205-22 | Sponsor Protocol Number: SSAT047 | Start Date*: 2012-10-02 |
Sponsor Name:St Stephen's AIDS Trust | ||
Full Title: A phase III, open-label, multi centre pilot study to assess the feasibility of switching, individuals receiving Atripla or Kivexa plus Efavarinz with continuing Central Nervous System (CNS) toxicit... | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005351-27 | Sponsor Protocol Number: 2015CD007B | Start Date*: 2016-02-17 | ||||||||||||||||
Sponsor Name:Royal Brompton & Harefield NHS Foundation Trust | ||||||||||||||||||
Full Title: A randomised controlled pilot trial of the feasibility and safety of therapy withdrawal in asymptomatic patients with a prior diagnosis of dilated cardiomyopathy & recovered cardiac function. | ||||||||||||||||||
Medical condition: Dilated Cardiomyopathy with recovered cardiac function | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020047-12 | Sponsor Protocol Number: P090202 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Etude de l'effet d'un traitement préventif par Nebivolol sur l'apparition et la progression de la dysfonction cardiaque chez les enfants atteints de dystrophie de Duchenne | |||||||||||||
Medical condition: Enfants atteints de dystrophie de Duchenne | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
